Find, compare & contact
Magnesium silicate
API Manufacturers & Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Magnesium silicate API 1343-88-0?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Magnesium silicate. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Magnesium silicate
- Synonyms:
- Cas Number:
- 1343-88-0
- DrugBank number:
- DB13249
- Unique Ingredient Identifier:
- 9B9691B2N9
General Description:
Magnesium silicate, identified by CAS number 1343-88-0, is a notable compound with significant therapeutic applications. Magnesium silicate is a compound of magnesium oxide and silicon. It is the magnesium salt of silicic acid containing an unspecified amount of water. The molecular formula can be expressed more clearly as MgSiO3.xH2O. It is known as talc and it presents many uses in the cosmetic industry, food industry and pharmaceutical industry. Under the FDA, magnesium silicate is determined as a member of the substances generally recognized as safe (GRAS) to be used as an anticaking agent.
Indications:
This drug is primarily indicated for: Magnesium silicate is used to absorb moisture, prevent caking, and to improve the feel of a product. In the pharmaceutical companies, it is used as a dietary supplement, as part of the formulation ingredients in drug production, in antacid and antiulcer preparations, as a component of antiepileptic drugs, in antifungal topical agents and in the treatment of acne and as a facial moisturizer. When complexed with arginine, magnesium silicate can be used as an antiatherosclerotic agent and to promote bone and cartilage formation in mammals. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.
Metabolism:
Magnesium silicate undergoes metabolic processing primarily in: The very low absorption of magnesium silicate makes its pharmacokinetic properties not relevant. This metabolic pathway ensures efficient processing of the drug, helping to minimize potential toxicity and side effects.
Absorption:
The absorption characteristics of Magnesium silicate are crucial for its therapeutic efficacy: Orally administered magnesium silicate is rapidly neutralized in the stomach and it forms magnesium chloride and silicon dioxide. From the modified portion, some of the formed magnesium is absorbed. The very low absorption of magnesium silicate makes its pharmacokinetic properties not relevant. The drug's ability to rapidly penetrate into cells ensures quick onset of action.
Half-life:
The half-life of Magnesium silicate is an important consideration for its dosing schedule: The very low absorption of magnesium silicate makes its pharmacokinetic properties not relevant. This determines the duration of action and helps in formulating effective dosing regimens.
Protein Binding:
Magnesium silicate exhibits a strong affinity for binding with plasma proteins: The very low absorption of magnesium silicate makes its pharmacokinetic properties not relevant. This property plays a key role in the drug's pharmacokinetics and distribution within the body.
Route of Elimination:
The elimination of Magnesium silicate from the body primarily occurs through: The very low absorption of magnesium silicate makes its pharmacokinetic properties not relevant. Understanding this pathway is essential for assessing potential drug accumulation and toxicity risks.
Volume of Distribution:
Magnesium silicate is distributed throughout the body with a volume of distribution of: The very low absorption of magnesium silicate makes its pharmacokinetic properties not relevant. This metric indicates how extensively the drug permeates into body tissues.
Clearance:
The clearance rate of Magnesium silicate is a critical factor in determining its safe and effective dosage: The very low absorption of magnesium silicate makes its pharmacokinetic properties not relevant. It reflects the efficiency with which the drug is removed from the systemic circulation.
Mechanism of Action:
Magnesium silicate functions by: As a supplement, magnesium silicate acts by replacing the factor that is missing. In the case of antacids, it is a non-absorbable antacid whose main activity is related to the absorption of hydrochloric acid. More specifically, magnesium silicate acts as a neutralizing and astringent agent. This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.
Toxicity:
Classification:
Magnesium silicate belongs to the class of inorganic compounds known as alkaline earth metal oxides. These are inorganic compounds containing an oxygen atom of an oxidation state of -2, in which the heaviest atom bonded to the oxygen is an alkaline earth metal, classified under the direct parent group Alkaline earth metal oxides. This compound is a part of the Inorganic compounds, falling under the Mixed metal/non-metal compounds superclass, and categorized within the Alkaline earth metal organides class, specifically within the Alkaline earth metal oxides subclass.
Categories:
Magnesium silicate is categorized under the following therapeutic classes: Agents that produce neuromuscular block (indirect), Alimentary Tract and Metabolism, Aluminum and magnesium containing antacids, Antacids, Drugs for Acid Related Disorders, Gastric Acid Lowering Agents, Magnesium Compounds, Metal cations, Metal divalent cations, Minerals, Silicates, Silicon Compounds. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Experimental Properties:
Further physical and chemical characteristics of Magnesium silicate include:
- Water Solubility: Insoluble
- Melting Point: 1910 ºC
Magnesium silicate is a type of Gastrointestinal Agents
Gastrointestinal Agents belong to the pharmaceutical API category that focuses on treating disorders and ailments related to the digestive system. These agents play a crucial role in addressing various gastrointestinal conditions, such as acid reflux, ulcers, irritable bowel syndrome (IBS), and inflammatory bowel disease (IBD).
One of the key types of gastrointestinal agents is proton pump inhibitors (PPIs), which work by reducing the production of stomach acid. PPIs help in treating conditions like gastroesophageal reflux disease (GERD) and peptic ulcers. Another essential class of agents is antacids, which neutralize excessive stomach acid, providing relief from heartburn and indigestion.
Gastrointestinal agents also include antispasmodics that alleviate abdominal cramps and spasms associated with conditions like IBS. These drugs work by relaxing the smooth muscles of the digestive tract. Additionally, there are drugs categorized as laxatives that aid in relieving constipation by promoting bowel movements.
Moreover, certain gastrointestinal agents act as antiemetics, effectively reducing nausea and vomiting. These drugs are particularly useful for patients undergoing chemotherapy or experiencing motion sickness.
Pharmaceutical companies develop and manufacture a wide range of gastrointestinal agents in various forms, including tablets, capsules, suspensions, and injections. These agents are typically formulated using active pharmaceutical ingredients (APIs) and other excipients to ensure their efficacy and safety.
In conclusion, gastrointestinal agents form a vital category of pharmaceutical APIs, providing relief from digestive disorders and improving overall gastrointestinal health. The availability of diverse agents catering to different conditions ensures that patients can receive targeted treatment for their specific gastrointestinal needs.
